Sometimes I must talk about NCAA football, cannot always be about NFL...so here is something for people with localized prostate cancer. 😜
The Phase 3 trial of CAN-2409 for intermediate- to high-risk localized prostate cancer has been completed, meeting its primary endpoint. The study demonstrated a 30% reduction in the risk of disease recurrence or death compared to radiation therapy alone, with a 14.5% improvement in disease-free survival (DFS) at 54 months. Patients also showed higher pathological complete response rates (80.4% vs. 63.6%). The treatment was well-tolerated, with only mild to moderate flu-like symptoms reported. Based on these results, Candel Therapeutics plans to seek regulatory approval for CAN-2409.
Update on Prostate Cancer Vaccines that I follow... another year is gone...